Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

INTRODUCTION: Hepatitis B virus (HBV) infection is associated with the onset of several major liver diseases. Inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) may be successfully treated with PEGylated interferon-α2b (PEG-IFNα2b)-based antiviral therapy; however, studies on this treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan, Qi, Min, Liao, Chengjin, Xun, Jinrui, Zou, Ju, Huang, Haiyue, Long, Li-Yuan, Chen, Jun, Fan, Xuegong, Chen, Ruochan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572934/
https://www.ncbi.nlm.nih.gov/pubmed/34350562
http://dx.doi.org/10.1007/s40121-021-00511-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572934/
https://www.ncbi.nlm.nih.gov/pubmed/34350562
http://dx.doi.org/10.1007/s40121-021-00511-w

Ejemplares similares